Cancellation of state registration. Bromergon

February 10, 2017
Active substances:
Trade names:
ICD-10:
II.D10-D36.D35.2    Benign neoplasm of pituitary gland
IV.E20-E35.E22.1    Hyperprolactinemia
IV.E20-E35.E23.0    Hypopituitarism
IV.E20-E35.E28    Dysfunction of the ovaries
IV.E20-E35.E28.2    Polycystic ovary syndrome
VI.G20-G26.G20    Parkinson's disease
VI.G20-G26.G21    Secondary Parkinsonism
XIV.N40-N51.N46    Male infertility
XIV.N60-N64.N60    Benign breast dysplasia
XIV.N60-N64.N61    Inflammatory diseases of the breast
XIV.N60-N64.N64.4    Mammalgia
XIV.N80-N98.N91    Absence of menstruation, meager and rare menstruation
XIV.N80-N98.N94.3    Premenstrual tension syndrome
XIV.N80-N98.N97    Female infertility
Bromocriptine, Bromergrone, a prolactin secretion inhibitor, an antiparkinsonian drug, Parkinson's disease, hyperprolactinaemia, pituitary neoplasm, ovarian dysfunction, male infertility, female infertility, mastodinia, mammary gland dysplasia

The Ministry of Health of the Russian Federation in accordance with Article 32 of the Federal Law of 12.04.2010 No. 61-FZ "On the circulation of medicines" decided to abolish state registration and exclude from the state register of medicinal products for medical use of the medicinal product (registration certificate P N008603 from 04.04.2012 issued by Sandoz dd, Slovenia):

Bromergon (trade name of the medicinal product)

Bromocriptine (international non-proprietary or grouping or chemical name)

tablets, 2.5 mg (dosage form, dosage)

Lekd, Slovenia Verovskova 57, 1526 Ljubljana, Slovenia (name and address of the location of the manufacturer of the medicinal product)

on the basis of filing an application by an authorized legal entity of ZAO Sandoz to cancel the state registration of the medicinal product.